Cerebrolysin

Cerebrolysin is an injectable mixture of low-molecular-weight neuropeptides and free amino acids made by enzymatic digestion of purified pig brain proteins; it also contains trace minerals such as magnesium, phosphorus, potassium, and selenium ¹⁹. It crosses the blood-brain barrier and works as a broad neuroprotective and neurorestorative signal rather than a single-target drug ¹⁹.

The preparation has been in clinical use for more than 50 years, mainly in Russia, Eastern Europe, China, and parts of Asia, and it is registered in about 50 countries, though not in the United States ¹⁹. Most studies test it as an add-on therapy for acute ischemic stroke, recovery after traumatic brain injury, Alzheimer's disease, mild cognitive impairment, and, in small trials, ALS ¹.

The evidence is mixed. The independent Cochrane review found no mortality benefit in acute stroke, while newer registries and meta-analyses report earlier neurological improvement and better functional outcomes ¹.

Cerebrolysin mimics the brain's own neurotrophic factors, the signaling proteins that help neurons survive, grow, and form new connections. Proteomic analysis has mapped its constituent peptides to myelin basic protein and tubulin, and identified candidate anti-inflammatory sequences such as LLNLQPPPR and the antioxidant peptide WPFPR ²⁰. Instead of occupying one receptor, Cerebrolysin appears to tune a network of signals that includes BDNF, NGF, IGF-1, and VEGF ¹⁹.

Animal and cell studies show several downstream effects. In aging mice, it increased dendritic spine density and BDNF expression in memory-related brain regions ²⁵. After experimental stroke, Sonic hedgehog signaling drove the generation of new brain cells, and blocking that pathway abolished the effect ²⁶. In ischemia-reperfusion models, it activated the Keap1/Nrf2 antioxidant pathway and reduced inflammatory cytokines ²⁷. Human biomarker data in Alzheimer's disease show reductions in amyloid-beta and tau species in neuronal-derived vesicles compared with donepezil alone ¹⁵.

No formal human half-life is published, and the peptide mixture is heterogeneous. Trial effects often appear after the infusion course ends, which fits a plasticity-inducing mechanism rather than a drug that only acts while present ³⁵.

Cerebrolysin's best-documented effects are on early neurological recovery when it is layered onto standard stroke care or rehabilitation.

• Acute stroke recovery. A meta-analysis of 14 randomized trials found a 1.39-point greater NIHSS improvement, without excess mortality ². The C-REGS2 registry reported better day-90 disability and cognition scores ³. The Cochrane review, by contrast, found no effect on death ¹.
• Hemorrhagic transformation protection. When added to alteplase, symptomatic bleeding into damaged brain tissue occurred less often, with an odds ratio of 0.248 ⁵. In thrombectomy cohorts, symptomatic intracranial hemorrhage risk was lower, with a risk ratio of 0.12 ⁹.
• Post-stroke aphasia. In the ESCAS randomized trial, Cerebrolysin plus speech therapy produced 14.8 additional points on the Western Aphasia Battery at day 90 ⁴.
• Traumatic brain injury. A prospective cohort reported better consciousness scores at discharge and higher 6-month survival, 59.4% versus 27.8% ¹⁰. A meta-analysis found Glasgow Coma Scale and outcome gains without a mortality change ¹¹.
• Alzheimer's disease and MCI. A dose-finding randomized trial showed global clinical improvement at week 24 across 10, 30, and 60 mL daily doses ¹⁴. Open comparative cohorts report fewer conversions from mild cognitive impairment to dementia over three years ¹⁶.
• ALS. One small phase II randomized trial reported ALSFRS-R changes of +2.3 versus -0.9 at month 1, maintained through month 3 ¹³.
• Diabetic neuropathy. Support is preclinical and observational; a mouse model showed sciatic nerve improvement ³².
• Mortality. Current randomized evidence does not support a survival benefit in acute stroke ¹. Nonmedical cognitive-enhancement use among students is documented in survey data, but that reports use patterns rather than efficacy ³⁴.

Published Cerebrolysin protocols almost always use flat adult doses rather than body-weight adjustment. The 30 mL daily intravenous dose dominates acute stroke and traumatic brain injury research ³.

• Acute ischemic stroke with or without reperfusion: 30 mL IV daily for 10 to 14 days, started within 48 hours ³.
• Thrombectomy adjunct: 30 mL IV started within 8 hours and continued to day 21, with a repeat 21-day course at days 69 to 90 ⁷.
• Post-stroke aphasia: 10-day cycles repeated across three intervals, combined with speech-language therapy ⁴.
• Moderate traumatic brain injury: 30 mL IV daily for 10 days ¹⁰.
• Alzheimer's disease: 10 to 60 mL IV daily, 5 days per week for 4 weeks, then 2 days per week for 8 weeks ¹⁴.
• Mild cognitive impairment and dementia prevention: 20 mL per infusion for 20 infusions, repeated annually for 3 years in comparative cohorts ¹⁶.
• ALS add-on: 10 mL IV daily, 5 days per week for month 1, then 3 days per week for months 2 to 3 ¹³.
• Postoperative cervical myelopathy: 5 mL diluted in 100 mL saline daily for 10 to 21 days ⁵⁰.

Adult dosing is flat across trials, and the 30 mL reference dose is diluted in normal saline and infused over roughly 60 minutes ¹⁸. Pediatric research uses a weight-based exception: 0.1 mL/kg intramuscular weekly in high-risk preterm infants ⁵².

Cerebrolysin is supplied as a ready-to-use sterile aqueous solution in single-use glass ampoules, not as a lyophilized powder, so it does not follow the usual peptide reconstitution steps with bacteriostatic water ¹⁹. The preparation is made by controlled enzymatic digestion of porcine brain proteins, and its active peptide species are detectable by mass spectrometry ²⁰.

For intravenous research protocols, the ampoule contents are diluted into normal saline rather than bacteriostatic water. Trial examples include 5 mL diluted in 100 mL normal saline over about 30 minutes ⁵⁰, and 30 mL infused over 60 minutes ¹⁸. Do not co-infuse Cerebrolysin with other drugs through the same line; the CEREHETIS trial used a separate line when it was given with alteplase ⁵.

Unopened ampoules are stored at 15 to 25 degrees Celsius, protected from light, and are not frozen. The solution contains no preservatives, so ampoules are single-use; any unused portion is discarded after opening, and partial ampoules are not stored. Diluted infusion admixtures should be used promptly or refrigerated and used within 24 hours.

Life-threatening anaphylaxis after IV administration has been reported, so visual inspection of the solution and a slow initial infusion are part of safe research handling ²⁸. The interactive calculator below handles liquid volume and normal saline dilution for research preparation.

No formal drug interaction studies exist for Cerebrolysin, so most information comes from combination arms of clinical trials and observational data.

• Alteplase. In the CEREHETIS trial, 30 mL daily plus alteplase reduced symptomatic hemorrhagic transformation, odds ratio 0.248, with no excess Cerebrolysin-attributed serious adverse events ⁵. A post hoc analysis suggests the benefit concentrated in patients at moderate-to-high bleeding risk ⁶.
• Mechanical thrombectomy. Observational data report lower symptomatic intracranial hemorrhage and mortality when Cerebrolysin follows thrombectomy ⁹. A 12-month analysis found improved functional independence ⁸.
• Citicoline. A retrospective traumatic brain injury comparison trended toward better 6-month outcome with the combination, but the difference was not statistically significant ⁶¹.
• Donepezil. In Alzheimer's biomarker research, the combination reduced amyloid-beta and tau measures more than donepezil alone ¹⁵.
• Riluzole. In a small ALS randomized trial, Cerebrolysin plus riluzole was well tolerated and improved ALSFRS-R ¹³.
• Antidepressants and lithium. Cohort data report improved depression and cognition with Cerebrolysin augmentation in elderly patients ⁶⁵. Lithium potentiation is supported only by animal data ⁶⁴.
• Antiepileptic drugs. In 38 patients with stable epilepsy, Cerebrolysin did not increase seizure frequency ⁵⁸.
• Speech therapy. The ESCAS trial showed that Cerebrolysin plus speech therapy produced larger aphasia gains than therapy plus placebo ⁴.
• rTMS. A three-arm traumatic brain injury trial found Cerebrolysin plus repetitive transcranial magnetic stimulation safe but missed its primary cognitive endpoint ¹².

For supplements with antiplatelet potential, such as fish oil or ginkgo, no published Cerebrolysin interaction data exist, and research should account for this uncertainty during acute reperfusion protocols.

Tolerance or tachyphylaxis has not been reported in Cerebrolysin trials, and no withdrawal syndrome appears in the safety literature ¹. Even so, the published course structures are finite and often spaced.

• Acute courses. CEREHETIS used 30 mL daily for 14 days ⁵. Moderate traumatic brain injury research used 30 mL daily for 10 days ¹⁰.
• Repeat courses. A thrombectomy-matched cohort used a 21-day course followed by a second 21-day course at days 69 to 90, with continued functional gains at 12 months ⁷.
• Tapered schedules. The Alzheimer's dose-finding trial used 5 days per week for 4 weeks, then 2 days per week for 8 weeks ¹⁴. The ALS pilot used 5 days per week for month 1, then 3 days per week ¹³.
• Annual preventive courses. Mild cognitive impairment cohorts used 20 infusions once a year for three years ¹⁶.
• Community elective use. Community protocols typically describe 4 to 6 week courses repeated 1 to 3 times per year, with gaps of at least 6 to 8 weeks and cumulative exposure around 300 mL per block.

The off-periods are not washouts in the pharmacological sense; recovery and plasticity can proceed between courses ⁷. The rationale for limited courses also reflects exposure control, since the Cochrane review flagged a possible increase in non-fatal serious adverse events on the 30 mL for 10 days schedule ¹.

Most published Cerebrolysin combinations are neurorecovery pairings rather than self-directed nootropic stacks. The combinations with human data are:

• Citicoline. This is the most evidence-backed combination. Both agents upregulate BDNF in stressed neural cells ³⁸, and a retrospective traumatic brain injury cohort showed a non-significant trend favoring the pair ⁶¹.
• Donepezil. Cerebrolysin plus donepezil produced stronger amyloid and tau biomarker reductions in Alzheimer's research ¹⁵.
• Riluzole. This combination was the design of the positive ALS pilot randomized trial ¹³.
• Speech and physical rehabilitation. Not a compound, but the strongest effect modifier. ESCAS paired Cerebrolysin with speech-language therapy ⁴, and extended physiotherapy improved upper-limb recovery in another randomized trial ⁵⁴.
• Nootropics. A 398-patient Vietnamese stroke study combined Cerebrolysin with nootropic therapy without drug-related adverse events ⁶⁸.
• BPC-157, Semax, or Selank. No direct interaction data exist. Because their neurotrophic and anti-inflammatory mechanisms overlap, research may need to consider redundancy, and community practice tends to separate neurorecovery courses rather than stack them simultaneously.

For peptide-peptide stacking, the main evidence-based caution is product identity: preparations marketed as Cerebrolysin-like have shown materially different peptide composition and less neurotrophic activity ²⁰.

Cerebrolysin is not FDA-approved and is not marketed in the United States ³¹. It appears in no US, EU, or UK dementia guideline and is absent from the WHO Model Essential Medicines List ¹⁷.

Internationally, it is registered in roughly 50 countries, concentrated in Eastern Europe, the Commonwealth of Independent States, and parts of Asia ³¹. It is included on several CIS national essential medicines lists and is recommended in Russian Alzheimer's guidelines, the only surveyed guideline to do so ¹⁷. Asian availability was reported in about one-third to one-half of surveyed countries and regions, with usage lower where national guidelines omit the drug ⁷⁶.

No DEA scheduling status is documented in the literature, and no WADA or USADA anti-doping data are published. Injectable peptide preparations that are not approved for human use can fall under WADA category S0, so competitive athletes should verify current classification with their national anti-doping organization before any research participation.

Across pooled randomized trials, Cerebrolysin's adverse-event profile is similar to placebo. A 12-trial safety meta-analysis found no significant differences, with the lowest serious adverse event rate observed at the 50 mL dose ²⁹. A 14-trial meta-analysis reported serious adverse events at a risk ratio of 1.08 ².

• Common effects. Headache and dizziness are the most commonly reported effects, and they tend to be mild and transient ¹⁹. Community reports add injection-site irritation and flushing.
• Serious adverse event signal. The Cochrane review flagged a possible increase in non-fatal serious events on the 30 mL for 10 days schedule, risk ratio 2.87, but no mortality increase ¹.
• Anaphylaxis. One laboratory-confirmed life-threatening reaction after IV administration is documented, so first infusions warrant observation ²⁸.
• Bleeding. Contrary to a common worry, Cerebrolysin reduced rather than increased hemorrhagic transformation in stroke trials, including with alteplase and thrombectomy ⁵.
• Seizures. In patients with stable epilepsy, Cerebrolysin did not increase seizure frequency ⁵⁸.
• Pregnancy and severe organ disease. No human safety data exist for pregnancy or breastfeeding, and kinetics in severe renal or hepatic failure are unstudied.

The main practical safety measures from the literature are allergy history before first infusion, observation during early infusions, and awareness that the strongest pooled harm signal sits with the 30 mL for 10 days stroke schedule ¹.